Published in Int J Cancer on March 15, 1977
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A (2003) 7.30
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol (1986) 2.28
Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med (1991) 2.20
Characterization of tumor cell lines derived from murine gammaherpesvirus-68-infected mice. J Virol (1996) 2.19
Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci U S A (1979) 1.90
Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dualtropic murine leukemia virus (MuLV). Am J Pathol (1982) 1.66
Epstein-Barr virus induces aggressive lymphoproliferative disorders of human B cell origin in SCID/hu chimeric mice. J Clin Invest (1990) 1.49
Integrated viral DNA sequences in Epstein-Barr virus-converted human lymphoma lines. J Virol (1978) 1.43
Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci U S A (1986) 1.38
Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest (1991) 1.20
Characterization of Epstein-Barr virus-induced lymphoproliferation derived from human peripheral blood mononuclear cells transferred to severe combined immunodeficient mice. Am J Pathol (1990) 0.99
Epstein-Barr virus transformation of human pre-B cells. J Exp Med (1983) 0.96
Persistence of human adenovirus 5 in human cord blood lymphoblastoid cell lines transformed by Epstein-Barr virus. Infect Immun (1980) 0.95
Different Epstein-Barr virus expression in lymphomas from immunocompromised and immunocompetent patients. Am J Pathol (1990) 0.93
E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma. Cancer Res (2009) 0.92
Comparison of cell-surface glycoproteins of rat hepatomas and embryonic rat liver. Br J Cancer (1977) 0.90
Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. PLoS One (2013) 0.88
Malignant transformation of Bloom syndrome B-lymphoblastoid cell lines by carcinogens. Proc Natl Acad Sci U S A (1985) 0.84
The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. PLoS One (2014) 0.79
Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells. Oncoscience (2014) 0.77
Serial transplantation of a human T-cell acute lymphoblastic leukaemia line into nude mice. Br J Cancer (1981) 0.77
Human non-Hodgkin's malignant lymphomas serially transplanted in nude mice conditioned with whole-body irradiation. Br J Cancer (1989) 0.75
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer (1973) 14.90
Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer (1976) 14.08
EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature (1970) 8.08
30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial. Lancet (2006) 7.88
Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res (1968) 7.53
The role of gene dosage and genetic transpositions in carcinogenesis. Nature (1981) 5.58
Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proc Natl Acad Sci U S A (1974) 5.13
Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. J Exp Med (1973) 5.03
Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. Biomedicine (1975) 4.68
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology (1975) 4.48
Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer (1976) 4.35
Evolution of tumours and the impact of molecular oncology. Nature (1985) 4.24
Specific chromosomal translocations and the genesis of B-cell-derived tumors in mice and men. Cell (1983) 4.22
The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (2007) 4.22
In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene (1993) 4.03
Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer (1988) 4.03
Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology (1979) 4.02
Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94
Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A (1966) 3.56
A massive binary black-hole system in OJ 287 and a test of general relativity. Nature (2008) 3.50
Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med (1976) 3.49
Suppression of malignancy by cell fusion. Nature (1969) 3.41
Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid. J Virol (1976) 3.33
Fasting capillary glucose as a screening test for gestational diabetes mellitus. BJOG (2006) 3.23
Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol (1970) 3.17
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer (1967) 3.04
Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Exp Cell Res (1975) 3.02
Relation between Epstein-Barr viral and cell membrane immunofluorescence of Burkitt tumor cells. I. Dependence of cell membrane immunofluorescence on presence of EB virus. J Exp Med (1968) 3.01
A primordial tRNA modification required for the evolution of life? EMBO J (2001) 3.01
Demonstration of two distinct components in the early antigen complex of Epstein-Barr virus-infected cells. Int J Cancer (1971) 3.00
The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer (1971) 2.96
Nonrandom chromosome changes involving the Ig gene-carrying chromosomes 12 and 6 in pristane-induced mouse plasmacytomas. Cell (1979) 2.92
K562--a human erythroleukemic cell line. Int J Cancer (1979) 2.84
Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int J Cancer (1972) 2.80
Relationship between Epstein-Barr virus (EBV) DNA and the EBV-determined nuclear antigen (EBNA) in Burkitt lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer (1974) 2.80
Phenotypic and cytogenetic characteristics of human B-lymphoid cell lines and their relevance for the etiology of Burkitt's lymphoma. Adv Cancer Res (1982) 2.68
Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A (1974) 2.66
Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75). Int J Cancer (1977) 2.66
Polyclonal Ig production after Epstein-Barr virus infection of human lymphocytes in vitro. Nature (1977) 2.58
Antibody reactions to virus-specific early antigens (EA) in patients with cytomegalovirus (CMV) infection. Clin Exp Immunol (1974) 2.57
EB virus-induced B lymphocyte cell lines producing specific antibody. Nature (1977) 2.56
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Clinical and angiographic risk factors for stroke and death within 30 days after carotid endarterectomy and stent-protected angioplasty: a subanalysis of the SPACE study. Lancet Neurol (2008) 2.53
Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood (1999) 2.49
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst (2000) 2.41
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol (1979) 2.31
A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol (1995) 2.28
Linear association between cellular DNA and Epstein-Barr virus DNA in a human lymphoblastoid cell line. Proc Natl Acad Sci U S A (1973) 2.27
Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst (1973) 2.25
Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res (1981) 2.25
Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature (1990) 2.23
Tumor antigens. Annu Rev Microbiol (1966) 2.19
The action of DNA antagonists on Epstein-Barr virus (EBV)-associated early antigen (EA) in Burkitt lymphoma lines. Int J Cancer (1971) 2.18
Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol (1976) 2.18
Classification and biological nature of established human hematopoietic cell lines. Int J Cancer (1975) 2.16
Spontaneous regression of primary malignant melanomas with regional metastases. Cancer (1965) 2.15
Relationship between the sensitivity of EBV-carrying lymphoblastoid lines to superinfection and the inducibility of the resident viral genome. Int J Cancer (1973) 2.14
Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. Proc Natl Acad Sci U S A (1988) 2.12
Susceptibility to infection by the human immunodeficiency virus (HIV) correlates with T4 expression in a parental monocytoid cell line and its subclones. Virology (1987) 2.11
DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science (1989) 2.11
Epstein-Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies. Int J Cancer (1974) 2.10
Intracellular forms of Epstein-Barr virus DNA in human tumour cells in vivo. Nature (1976) 2.10
Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature (1980) 2.08
Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000-dalton subunit. J Virol (1980) 2.07
Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res (1990) 2.07
gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci U S A (1985) 2.07
High-frequency establishment of human immunoglobulin-producing lymphoblastoid lines from normal and malignant lymphoid tissue and peripheral blood. Int J Cancer (1971) 2.06
DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci U S A (1973) 2.02
Search for host defenses in Burkitt lymphoma: membrane immunofluorescence tests on biopsies and tissue culture lines. Cancer Res (1967) 2.01
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.99
5-Azacytidine up regulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line rael. J Virol (1989) 1.99
Nasopharyngeal carcinoma. X. Presence of epstein-barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya. Int J Cancer (1975) 1.95
Epstein-Barr virus susceptibility of normal human B lymphocyte populations. J Exp Med (1984) 1.94
A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics (1972) 1.93
Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene (1993) 1.91
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
High-level expression of the Epstein-Barr virus EBNA1 protein in CV1 cells and human lymphoid cells using a SV40 late replacement vector. Gene (1986) 1.90
MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res (1999) 1.90
Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci U S A (1979) 1.90
Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci U S A (1977) 1.87
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation (2001) 1.83
Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med (1985) 1.83
The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A (2001) 1.81
EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients. Int J Cancer (1976) 1.81